HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model; International Journal of Molecular Sciences; Vol. 20, iss. 10

Bibliografske podrobnosti
Parent link:International Journal of Molecular Sciences
Vol. 20, iss. 10.— 2019.— [2399, 19 p. ]
Korporativna značnica: Национальный исследовательский Томский политехнический университет Физико-технический институт Лаборатория № 31 ядерного реактора
Drugi avtorji: Sokolova E. A. Evgeniya Aleksandrovna, Shilova O. N. Olga Nikolaevna, Kiselyova D. V. Darjya Vladimirovna, Shulga A. A. Aleksey Anatolievich, Balalaeva I. V. Irina Vladimirovna, Deev S. M. Sergey Mikhaylovich
Izvleček:Title screen
High immunogenicity and systemic toxicity are the main obstacles limiting the clinical use of the therapeutic agents based on Pseudomonas aeruginosa exotoxin A. In this work, we studied the immunogenicity, general toxicity and antitumor effect of the targeted toxin DARPin-LoPE composed of HER2-specific DARPin and a low immunogenic exotoxin A fragment lacking immunodominant human B lymphocyte epitopes. The targeted toxin has been shown to effectively inhibit the growth of HER2-positive human ovarian carcinoma xenografts, while exhibiting low non-specific toxicity and side effects, such as vascular leak syndrome and liver tissue degradation, as well as low immunogenicity, as was shown by specific antibody titer. This represents prospects for its use as an agent for targeted therapy of HER2-positive tumors.
Jezik:angleščina
Izdano: 2019
Teme:
Online dostop:https://doi.org/10.3390/ijms20102399
Format: Elektronski Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664213
Opis
Izvleček:Title screen
High immunogenicity and systemic toxicity are the main obstacles limiting the clinical use of the therapeutic agents based on Pseudomonas aeruginosa exotoxin A. In this work, we studied the immunogenicity, general toxicity and antitumor effect of the targeted toxin DARPin-LoPE composed of HER2-specific DARPin and a low immunogenic exotoxin A fragment lacking immunodominant human B lymphocyte epitopes. The targeted toxin has been shown to effectively inhibit the growth of HER2-positive human ovarian carcinoma xenografts, while exhibiting low non-specific toxicity and side effects, such as vascular leak syndrome and liver tissue degradation, as well as low immunogenicity, as was shown by specific antibody titer. This represents prospects for its use as an agent for targeted therapy of HER2-positive tumors.
DOI:10.3390/ijms20102399